Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Clinical evidence

OASIS-HAE

23 evidence topics · 5 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack rate per four weeks as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual treated populations
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline demographics
CharacteristicReported value
Mean age, years (SD)“37 (14)”
Female, n (%)“48 (53)”
Efficacy results
Mean attack rate per four weeks: weeks 1–25 in the publication
Health-related quality of life and patient-reported outcomes
Angioedema Control Test: change from baseline and disease control at week 24
Safety results
Injection-site reactions
TreatmentParticipants, n (%)
Donidalorsen every four weeks, n=45“11 (24)”
Donidalorsen every eight weeks, n=23“1 (4)”
Placebo, n=22“1 (5)”
Study limitations
Summary

The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.